A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

NCT06169891 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Gout

Interventions

DRUG: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
OTHER: Placebo
DRUG: Compound Betamethasone Injection
OTHER: Placebo

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.